< Back to latest news & events

News

New Practice at the EPO: Divisional Applications and Sequence Listings

November 2023

Safeguard measure: Excess page fees on ST.25 sequence listings included as part of a divisional application to be waived by the EPO.

Following the implementation of WIPO Sequence standard ST.26, the EPO has required that new divisional applications filed on or after 1 July 2022 require a sequence listing in the ST.26 format, even when the parent application contained an ST.25 standard compliant sequence listing. This practice has been met with concern from practitioners regarding the risk of added subject matter.

To address the concerns around the risk of adding or losing subject matter, the EPO has announced a new safeguard measure. The safeguard measure permits applicants to file the parent application’s ST.25 sequence listing in PDF format as part of the divisional application. Importantly, the ST.25 pages included as a safeguard are excluded from the page fee calculation. Alternatively, the divisional application may be filed by reference to the parent application. In doing so, applicants have the guarantee that the ST.25 sequence listing, which is part of the application, does not contain any additional subject-matter.  In any event, an ST.26 compliant sequence listing will still also need to be filed.

Page fees already paid for pages of sequence listings not complying with WIPO Standard ST.26 will not be refunded.

Full details are expected to be published in the November issue of the Official Journal.

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

T 1847/22: Procedural considerations in appeal: Re-ordering of requests and the impact on admissibility

Background This case concerned EP 3 085 344 B1, which relates to a wound pad, a self-adhesive member comprising a wound pad. The patent was opposed by two opponents. During …

Read article

Regulation of NGT plants in Europe- Polish Presidency proposes an alternative solution to the Patent ban

In the latest development on the new proposed legislation for the regulation of NGT (gene-edited) plants in the EU, the Polish Presidency have proposed an amendment which removes the proposed …

Read article

T 0295/22: EPO Technical Board of Appeal relies on “bonus effect” case law to find Amgen’s patent to orally administered apremilast lacking in inventive step

This case concerned Amgen’s European patent no. 2962690 for apremilast, a drug sold under the brand name Otezla®, licensed for the treatment of e.g., psoriasis and psoriatic arthritis.  The patent …

Read article
Event - 18th March 2025

Salzburg Seminar: Pitfalls in trade mark practice - What can be protected as a trade mark?

The registration of trade marks is a central component of trade mark protection – but which signs can actually be protected? In recent years, the national trade mark offices and …

Event details

Can the Chancellor’s so-called “Europe’s Silicon Valley” really replicate the innovative activity of its namesake?

The Chancellor of the UK, Rachel Reeves, recently unveiled plans to deliver an Oxford-Cambridge growth corridor that promises to boost the UK economy by up to £78 billion by 2035.  …

Read article

UPC’s CFI (Milan) extends deadline to file defence to infringement claim to align with parallel EPO appeal proceedings

Dainese S.p.A. v. Alpinestars S.p.A. & ors. UPC_CFI_472/2024 – Milan Local Division (Perrotti, Zana, Klein, Ashley) – 15 January 2025 The Milan Local Division granted a defendant’s request for an …

Read article